Exclusive-Bayer's new CEO plans to cut management jobs in prelude to overhaul
Reuters
Published Sep 14, 2023 17:17
Updated Sep 15, 2023 11:34
By Ludwig Burger and Patricia Weiss
FRANKFURT (Reuters) -Bayer's new CEO plans to cut management jobs to speed up decision-making as a first step to overhaul the embattled German industrial group, which is facing investor pressure to break up, three people familiar with the matter said.
The stock was up 1.3% at 0900 GMT on the news on Friday, outperforming a gain of about 1% in Germany's benchmark index DAX and the STOXX Europe 600 Health Care which was 0.6% higher.
Bill Anderson, at the helm since June, is keen to show investors speedy improvements and buy himself time to lay out broader restructuring plans over the next few months, the sources said. They declined to be identified because the details are confidential.
Anderson plans to soon present initial plans for cutbacks at an internal strategy meeting, one of the sources said, while another said the measures would affect middle-to-upper layers of management, resulting in as yet unspecified one-off costs for golden handshakes for departing employees.
The number of jobs affected and timing of an announcement are not known.
A Bayer (ETR:BAYGN) spokesperson declined to comment.
"A sense of urgency is evident in the new CEO. The old management often acted as if they had all the time in the world," said Markus Manns, portfolio manager at German mutual fund firm Union Investment, when asked to comment on the Reuters report.
He noted that Anderson had shown a clear distaste for bureaucratic structures at his previous employer, Roche.
"Anderson seems set to not leave any stone unturned at Bayer. Carrying on as before is simply not an option," he added.
"Bayer is facing investor pressure to break up, so the news might improve sentiment, but it isn’t the news the market is waiting for," said one stock trader, who declined to be identified.
Anderson told analysts after the release of second-quarter results that too much red tape - alongside the company's debts and lawsuits related to weedkiller Roundup and chemicals known as PCB - meant the company was missing out on opportunities.
"The litigation overhang, the corporate bureaucracy, debt levels, these all weigh on our ability to focus on the mission," he said in August.
He added at the time that he will change from annual to 90-day budgeting cycles, and let teams of people close to customers make business decisions, rather than a layer of management above them.
MARKET CONCERNS
Among the people leaving the maker of drugs and pesticides under the overhaul, for which the CEO has hired consultancy firm McKinsey, is head of group strategy Oliver Kohlhaas, who will not be replaced, two of the sources said.
Kohlhaas and McKinsey declined to comment.
Anderson's appointment was widely welcomed by shareholders as a qualified CEO pick to overhaul Bayer, replacing predecessor Werner Baumann, who had drawn criticism for not being responsive to capital market concerns.
Get The App
But the new CEO will likely have only a short respite period to come up with concrete strategic proposals. Investor Artisan Partners told Reuters last month the company needs to separate its three main businesses - agriculture, prescription drugs and consumer health products.
Activist Bluebell Capital Partners called for a breakup earlier this year. Other top investors, including mutual funds group Deka, had railed against the company's previous leadership. Some have said an easy fix would be to separate the healthcare and agricultural businesses.
Anderson has been tasked with reviving Bayer's share price, which has underperformed rivals, weighed down by the lingering costs of U.S. weedkiller litigation.
Anderson said last month he was not ruling out any options as part of his review of the company's strategy and structure, saying he was "leaving no stone unturned".
He added he would provide an initial update in the coming months and detailed plans in early 2024.
The company said in an unscheduled statement last month that it was projecting a steeper fall in earnings and zero free cash flow, in what some analysts suggested was Anderson seeking to get bad news out quickly to allow for a fresh start.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.